Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/75674
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBenjamin A. Rybickien_US
dc.contributor.authorSudha M. Sadasivanen_US
dc.contributor.authorYalei Chenen_US
dc.contributor.authorOleksandr Kravtsoven_US
dc.contributor.authorWatchareepohn Palangmonthipen_US
dc.contributor.authorKanika Aroraen_US
dc.contributor.authorNilesh S. Guptaen_US
dc.contributor.authorSean Williamsonen_US
dc.contributor.authorKevin Bobbitten_US
dc.contributor.authorDhananjay A. Chitaleen_US
dc.contributor.authorDeliang Tangen_US
dc.contributor.authorAndrew G. Rundleen_US
dc.contributor.authorKenneth A. Iczkowskien_US
dc.date.accessioned2022-10-16T07:01:50Z-
dc.date.available2022-10-16T07:01:50Z-
dc.date.issued2021-05-01en_US
dc.identifier.issn20457634en_US
dc.identifier.other2-s2.0-85103383759en_US
dc.identifier.other10.1002/cam4.3850en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85103383759&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/75674-
dc.description.abstractGrowth and differentiation factor 15 (GDF-15), also known as macrophage inhibitory cytokine 1 (MIC-1), may act as both a tumor suppressor and promotor and, by regulating NF-κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation-related proteins affect prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for GDF-15 and NF-κB was done in a study of 503 case-control pairs matched on date, age, and race, nested within a historical cohort of 10,478 men. GDF-15 and NF-κB expression levels were positively correlated (r = 0.39; p < 0.0001), and both were significantly lower in African American (AA) compared with White men. In adjusted models that included both markers, the odds ratio (OR) for NF-κB expression was statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77–0.99, while GDF-15 expression was associated with a nominally increased risk, OR =1.06; p = 0.27; 95% CI =0.96–1.17. When modeling expression levels by quartiles, the highest quartile of NF-κB expression was associated with almost a fifty percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29–0.92). In stratified models, NF-κB had the strongest negative association with prostate cancer in non-aggressive cases (p = 0.03), older men (p = 0.03), and in case-control pairs with longer follow-up (p = 0.02). Risk associated with GDF-15 expression was best fit using nonlinear regression modeling where both first (p = 0.02) and second (p = 0.03) order GDF-15 risk terms were associated with significantly increased risk. This modeling approach also revealed significantly increased risk associated with GDF-15 expression for subsamples defined by AA race, aggressive disease, younger age, and in case-control pairs with longer follow-up. Therefore, although positively correlated in benign prostatic biopsies, NF-κB and GDF-15 expression appear to exert opposite effects on risk of prostate tumor development.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleGrowth and differentiation factor 15 and NF-κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detectionen_US
dc.typeJournalen_US
article.title.sourcetitleCancer Medicineen_US
article.volume10en_US
article.stream.affiliationsMailman School of Public Healthen_US
article.stream.affiliationsMedical College of Wisconsinen_US
article.stream.affiliationsHenry Ford Hospitalen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.